WEE1 Inhibitor: Clinical Development

被引：0
|
作者：
Anthony Kong
Hisham Mehanna
机构：
[1] University of Birmingham,Institute of Head and Neck Studies (InHANSE)
[2] King’s College London,Comprehensive Cancer Centre
来源：
Current Oncology Reports | 2021年 / 23卷
关键词：
WEE1 inhibitor; Adavosertib; AZD1775; TP53 mutation; Biomarker; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
    Garcia, Tamara B.
    Uluisik, Rizvan C.
    van Linden, Annemie A.
    Jones, Kenneth L.
    Venkataraman, Sujatha
    Vibhakar, Rajeev
    Porter, Christopher C.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [32] WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Saito, Hitoshi
    Yamamori-Morita, Tomoko
    Nakao, Takehiro
    Liu, Jie
    Mori, Shunta
    Yagishita, Shigehiro
    Hamada, Akinobu
    Shinno, Yuki
    Yoshida, Tatsuya
    Horinouchi, Hidehito
    Ohe, Yuichiro
    Watanabe, Shun-Ichi
    Yatabe, Yasushi
    Kitai, Hidenori
    Konno, Satoshi
    Kobayashi, Susumu S.
    Ohashi, Akihiro
    CANCER LETTERS, 2025, 611
  • [33] Identification of DNA methylation-regulated WEE1 with potential implications in prognosis and immunotherapy for low-grade glioma
    Zhong, Wang-Jing
    Zhang, Li-Zhen
    Yue, Feng
    Yuan, Lezhong
    Zhang, Qikeng
    Li, Xuesong
    Lin, Li
    CANCER BIOMARKERS, 2024, 40 (3-4) : 297 - 317
  • [34] Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
    Kim, Daehwan
    Chung, Heekyung
    Liu, Wen
    Jeong, Kangjin
    Ozmen, Tugba Y.
    Ozmen, Furkan
    Rames, Matthew J.
    Kim, Sangyub
    Guo, Xiao
    Jameson, Nathan
    de Jong, Petrus R.
    Yea, Steven
    Harford, Laurie
    Li, Jiali
    Mathews, Cara A.
    Doroshow, Deborah B.
    Charles, Vincent J.
    Kim, Doris
    Fischer, Kimberlee
    Samatar, Ahmed A.
    Jubb, Adrian
    Bunker, Kevin D.
    Blackwell, Kimberly
    Simpkins, Fiona
    Meric-Bernstam, Funda
    Mills, Gordon B.
    Harismendy, Olivier
    Ma, Jianhui
    Lackner, Mark R.
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [35] Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines
    Iannuzzi, Carmelina Antonella
    Indovina, Paola
    Forte, Iris Maria
    Di Somma, Sarah
    Malfitano, Anna Maria
    Bruno, Martina
    Portella, Giuseppe
    Pentimalli, Francesca
    Giordano, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 15
  • [36] Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer
    Gorecki, Lukas
    Andrs, Martin
    Korabecny, Jan
    CANCERS, 2021, 13 (04) : 1 - 23
  • [37] MiR-503-5p regulates cell epithelial-to-mesenchymal transition, metastasis and prognosis of hepatocellular carcinoma through inhibiting WEE1
    Jiang, S-P
    Li, Z-R
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (05) : 2028 - 2037
  • [38] Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells
    Hieber, Christoph
    Mustafa, Al-Hassan M.
    Neuroth, Sarah
    Henninger, Sven
    Wollscheid, Hans -Peter
    Zabkiewicz, Joanna
    Lazenby, Michelle
    Alvares, Caroline
    Mahboobi, Siavosh
    Butter, Falk
    Brenner, Walburgis
    Bros, Matthias
    Kraemer, Oliver H.
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 177
  • [39] Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol
    Kong, Anthony
    Good, James
    Kirkham, Amanda
    Savage, Joshua
    Mant, Rhys
    Llewellyn, Laura
    Parish, Joanna
    Spruce, Rachel
    Forster, Martin
    Schipani, Stefano
    Harrington, Kevin
    Sacco, Joseph
    Murray, Patrick
    Middleton, Gary
    Yap, Christina
    Mehanna, Hisham
    BMJ OPEN, 2020, 10 (03):
  • [40] Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
    Mita, Monica
    Sankhala, Kamalesh
    Abdel-Karim, Issam
    Mita, Alain
    Giles, Francis
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (12) : 1947 - 1954
12345